Recent patents in the treatment and prevention of leishmaniasis.

IF 1.8 Q3 PHARMACOLOGY & PHARMACY Pharmaceutical patent analyst Pub Date : 2023-09-01 Epub Date: 2023-12-08 DOI:10.4155/ppa-2023-0022
Sukhbir K Shahid
{"title":"Recent patents in the treatment and prevention of leishmaniasis.","authors":"Sukhbir K Shahid","doi":"10.4155/ppa-2023-0022","DOIUrl":null,"url":null,"abstract":"<p><p>Leishmaniasis, a neglected tropical disease, is caused by protozoal parasites of the genus <i>Leishmania</i>. Clinical manifestations vary from asymptomatic to lethal grade depending on the type of the disease. The currently available antileishmanial drugs suffer from considerable limitations. There is a dire need for better and safer drugs and/or vaccines to eradicate this disease. There are enormous developments ongoing in this field. Newer combinations of existing drugs and newer drugs targeting these intracellular parasites as well as their vectors are being tried to control the disease. Attempts to develop vaccines to enhance the immunity of the patient have shown some promise. This article is a peep into the recent patent developments in this field.</p>","PeriodicalId":20011,"journal":{"name":"Pharmaceutical patent analyst","volume":null,"pages":null},"PeriodicalIF":1.8000,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmaceutical patent analyst","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4155/ppa-2023-0022","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/12/8 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

Leishmaniasis, a neglected tropical disease, is caused by protozoal parasites of the genus Leishmania. Clinical manifestations vary from asymptomatic to lethal grade depending on the type of the disease. The currently available antileishmanial drugs suffer from considerable limitations. There is a dire need for better and safer drugs and/or vaccines to eradicate this disease. There are enormous developments ongoing in this field. Newer combinations of existing drugs and newer drugs targeting these intracellular parasites as well as their vectors are being tried to control the disease. Attempts to develop vaccines to enhance the immunity of the patient have shown some promise. This article is a peep into the recent patent developments in this field.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
治疗和预防利什曼病的最新专利。
利什曼病是一种被忽视的热带疾病,由利什曼属原生动物寄生虫引起。临床表现因疾病类型而异,从无症状到致命程度不等。目前可用的抗利什曼病药物存在相当大的局限性。我们迫切需要更好、更安全的药物和/或疫苗来根除这种疾病。这一领域正在取得巨大进展。人们正在尝试将现有药物和针对这些细胞内寄生虫及其载体的新药组合起来,以控制这种疾病。开发疫苗以增强患者免疫力的尝试也已初见成效。本文将对这一领域的最新专利进展进行介绍。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Pharmaceutical patent analyst
Pharmaceutical patent analyst PHARMACOLOGY & PHARMACY-
CiteScore
1.80
自引率
0.00%
发文量
22
期刊最新文献
Liraglutide innovations: a comprehensive review of patents (2014–2024) Esterase responsive release of anti-cancer agents from conjugated lipid nanocarrier and the regulatory considerations Catalyzing innovation in cancer drug discovery through artificial intelligence, machine learning and patency Patent highlights August-September 2023. Patent Highlights June-July 2023.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1